The new GSK logo acts as a sign that “always points the way ahead”, and is housed in a redesigned shape known as the “signal”. The new identity system was designed to flex, adapt and move to help ...

Image courtesy Johnson & Johnson The new Johnson & Johnson logo conforms to current pharma design trends, as can also be seen in the Kenvue identity and in GSK’s recent redesign (again by Wolff Olins) ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

After several years of anticipation, it’s a new GSK. And so far, the results look pretty good. The company, with facilities in Collegeville and Valley Forge, reported positive second quarter ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Sometimes the best new logo is the old one. It took DC Comics a long time to realise that, but it finally got there. Chief ...

In addition to established platform technologies, GSK is building new platforms such as the Multiple Antigen-Presenting System (MAPS) and mRNA, key to addressing the most complex diseases.

Questions remain about GSK’s ability to come up with new drugs and litigation over the antacid Zantac, and the stock still ...

GSK's specialty medicines segment showed strong performance, growing over 20% due to successful new launches. Additionally, GSK is currently undervalued, trading at £16.1, significantly below the ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50. The company’s shares opened today at p1,644. ...

A new treatment for urinary tract infections got a step closer to reality on Thursday. The pharma giant GSK said it has stopped two late-stage clinical studies early, because they've already shown ...